SIRT3 and cardiac hypertrophy: Based on the fact that both SIRT3 and PARP-1 consume NAD+ to exert their functions, we hypothesized that SIRT3 could inhibit cardiac hypertrophy by repressing PARP-1 activation in cardiomyocytes.